Boston Scientific Retained Earnings increased by 24.1% to $6.91B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 106.5%, from $3.35B to $6.91B. Over 5 years (FY 2020 to FY 2025), Retained Earnings shows an upward trend with a 18.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase signals strong historical profitability and reinvestment, while a decrease may indicate losses or significant dividend payouts.
This represents the cumulative net income earned by the company since its inception, minus any dividends paid to shareho...
A key metric for all established companies; growth rates are compared against peers to gauge long-term success.
retained_earnings| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$1.88B | -$1.47B | -$1.39B | -$1.30B | -$1.05B | -$876.00M | -$750.00M | -$450.00M | -$189.00M | $315.00M | $819.00M | $1.31B | $1.64B | $2.11B | $2.67B | $3.35B | $4.14B | $4.90B | $5.57B | $6.91B |
| QoQ Change | — | +21.6% | +5.5% | +6.9% | +19.0% | +16.6% | +14.4% | +40.0% | +58.0% | +266.7% | +160.0% | +60.4% | +24.7% | +28.6% | +26.9% | +25.2% | +23.8% | +18.2% | +13.7% | +24.1% |
| YoY Change | — | — | — | — | +44.1% | +40.5% | +46.1% | +65.3% | +82.0% | +136.0% | +209.2% | +392.0% | +967.2% | +568.9% | +226.4% | +154.7% | +152.8% | +132.5% | +108.4% | +106.5% |